{
    "nct_id": "NCT05537896",
    "official_title": "Prospective Evaluation of Xerava™ (Eravacycline) Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia",
    "inclusion_criteria": "* All patients receiving induction chemotherapy for treatment of acute leukemia or receiving preparative regimen for HSCT\n* Patient must provide informed consent.\n* Bilirubin ≤ 3 x the ULN and AST/ALT ≤ 5 x ULN\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Uncontrolled bacterial, viral or fungal infection at the time of study enrollment.\n* Urinary tract infection receiving active treatment\n* Acute pancreatitis (not necessary to work-up unless symptomatic)\n* History of known hypersensitivity to eravacycline, tetracycline, doxycycline, minocycline, tigecycline, sarecycline, oxytetracycline, or omadacycline\n* Pseudomonas infection within 30 days prior to study enrollment\n* Receiving strong inhibitors or inducers of cytochrome P450 3A4 will be excluded from the study (see Appendix B for complete list of medications)\n* Pregnant or lactating women",
    "miscellaneous_criteria": ""
}